➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Baxter
McKesson
Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Fenebrutinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Fenebrutinib?

Fenebrutinib is an investigational drug.

There have been 5 clinical trials for Fenebrutinib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 17th 2020.

The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, and Multiple Sclerosis, Chronic Progressive. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and [disabled in preview].

There are six US patents protecting this investigational drug and ninety-eight international patents.

Recent Clinical Trials for Fenebrutinib
TitleSponsorPhase
A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)Hoffmann-La RochePhase 3
Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)Hoffmann-La RochePhase 3
A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple SclerosisHoffmann-La RochePhase 3

See all Fenebrutinib clinical trials

Clinical Trial Summary for Fenebrutinib

Top disease conditions for Fenebrutinib
Top clinical trial sponsors for Fenebrutinib

See all Fenebrutinib clinical trials

US Patents for Fenebrutinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fenebrutinib   Start Trial Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase Genentech, Inc. (South San Francisco, CA)   Start Trial
Fenebrutinib   Start Trial Process for preparing BTK inhibitors Genentech, Inc. (South San Francisco, CA)   Start Trial
Fenebrutinib   Start Trial Heteroaryl pyridone and aza-pyridone compounds Genentech, Inc. (South San Francisco, CA)   Start Trial
Fenebrutinib   Start Trial Heteroaryl pyridone and aza-pyridone compounds Genentech, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fenebrutinib

Drugname Country Document Number Estimated Expiration Related US Patent
Fenebrutinib Argentina AR107751 2036-02-29   Start Trial
Fenebrutinib Australia AU2017227929 2036-02-29   Start Trial
Fenebrutinib Brazil BR112018069530 2036-02-29   Start Trial
Fenebrutinib Canada CA2997859 2036-02-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Baxter
McKesson
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.